95309-80-1 Usage
Explanation
The molecular formula represents the number of atoms of each element present in a molecule of the compound.
Explanation
The chemical structure describes the arrangement of atoms and the type of chemical bonds present in the compound.
Explanation
Functional groups are specific groups of atoms within a molecule that have characteristic chemical properties and reactivity.
Explanation
The various fields in which the compound is used, highlighting its versatility and importance in different industries.
Explanation
The physical state of a compound is determined by its molecular structure and intermolecular forces. However, this information is not provided in the material.
Explanation
Solubility refers to the ability of a compound to dissolve in a particular solvent. This information is not provided in the material.
Explanation
Reactivity describes how a compound reacts with other substances under specific conditions. This information is not provided in the material.
Chemical structure
Benzene derivative with a benzyl ether group and a benzyl sulfide group attached to the benzene ring
Functional groups
Benzyl ether and benzyl sulfide
Applications
Organic synthesis, building block for pharmaceuticals and agrochemicals, production of specialty chemicals, and reagent in chemical research
Potential applications
Development of new materials and drug discovery processes
Physical state
Likely a solid or liquid at room temperature (not specified in the material)
Solubility
Not specified in the material
Reactivity
Not specified in the material
Check Digit Verification of cas no
The CAS Registry Mumber 95309-80-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,5,3,0 and 9 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 95309-80:
(7*9)+(6*5)+(5*3)+(4*0)+(3*9)+(2*8)+(1*0)=151
151 % 10 = 1
So 95309-80-1 is a valid CAS Registry Number.
95309-80-1Relevant articles and documents
COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS
-
, (2018/07/31)
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
